Electrophysiological, structural and contractile properties comparable to CMCs; ability to inegrate structurally and functionally with host tissue |
Plurality of cell lineage for transplantation of specialized CMC subtypes (pacemaking, atrial, ventricular, etc.) and/or endothelial progenitor cells to induce angioenesis |
Retain an initial proliferative potential for colonization of the scar tissue |
In vitro, differentiate schemes give the opportunity to choose the ESC-maturation stage |
Ability to undergo genetic manipulation ex vivo to promote desirable characteristics (i.e. minimal immunogenicity; resistance to ischemia, apoptosis or antibiotics ) |
Clonal origin gives the opportunity for extensive characterization and genetic manipulation (e.g. decrease the expression of MHC, to preform an antibiotic-cell selection in vitro
|
Autologus origin |
Derivation of ESC lines specifically for each patient with somatic nuclear transfer |
Large quantities for transplantation |
Currently the only cell source with this potential property |